Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATACAND · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ATACAND | DRUG | - |
Inclusion Criteria: * Subjects between the ages of 30 and 65 (inclusive) at the time of the informed consent process * have an average clinic BP in the high normal range of \< 139/85-89 mmHg or 130-139/\< 89 mm Hg (high normal BP range) (mean systolic and/or diastolic pressure based on 3 consecutiv...
ATACAND is used for the treatment of hypertension, or high blood pressure. It is a small molecule cardiovascular therapy being developed by AstraZeneca PLC. The drug is currently in Phase 3 clinical development for this indication.
ATACAND is a small molecule that targets the angiotensin II receptor, a key component in blood pressure regulation. By blocking this receptor, it helps to lower blood pressure in patients with hypertension. This mechanism is central to its role in cardiovascular therapy.
ATACAND is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is responsible for the clinical development and potential commercialization of this hypertension treatment.
ATACAND is in Phase 3 clinical development for hypertension. It has completed one Phase 3 trial, the TROPHY study, which was a randomized, double-blind trial with 1,000 participants. The drug is still investigational and has not yet been approved for commercial use.
ATACAND has been studied in the TROPHY trial (NCT00227318), a Phase 3 study titled 'Candesartan Cilexetil Long-term Hypertension Prevention Trial'. This completed trial enrolled 1,000 patients with hypertension in the United States, with participants aged 30 years and older.
Yes, ATACAND is the brand name for candesartan cilexetil, as indicated by the TROPHY trial title. This medication is being developed for hypertension and is currently in Phase 3 clinical trials. It is important to note that it remains investigational and is not yet approved.